跳至主要内容
临床试验/NCT03238404
NCT03238404已完成不适用

The Application of Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in Enhanced Recovery After Surgery Programs for Radical Gastrectomy

JIANG Zhi-Wei1 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2015年8月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
88
试验地点
1
主要终点
Postoperative length of stay

研究概览

简要总结

Patients with advanced gastric cancer received neoadjuvant chemotherapy undergo enhanced recovery after surgery (ERAS) programs.

详细描述

In recent years, enhanced recovery after surgery (ERAS) programs were applied in gastrectomy in areas with a high prevalence of gastric cancer, such as China and Japan, confirming that ERAS programs accelerate the postoperative rehabilitation of gastric cancer patients without increasing the occurrence rate of postoperative complications. However, in most studies on ERAS for gastric cancer, patients who received neoadjuvant chemotherapy were excluded. Investigators designed this study aimed to evaluate whether patients who receive neoadjuvant chemotherapy can enrolled into enhanced recovery after surgery programs for locally advanced gastric cancer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with locally advanced gastric cancer.
  • Age older than 18 and younger than 75 years.
  • American Society of Anesthesiologists (ASA) class: I-III.
  • Participants can describe the symptom objectively and cooperate actively.
  • Written informed consent

排除标准

  • Patients allergic to oxaliplatin, tegafur gimerac etc.
  • Patients with ischemic heart disease, cerebrovascular disease and peripheral vascular disease, or cardiac function > II (NYHA)
  • Patients with complications (bleeding, perforation and obstruction) caused by gastric cancer.
  • Patients with severe liver and renal dysfunction (Child - Pugh ≥ 10; Cr < 25 ml/min).
  • Patients who require simultaneous surgery for other diseases.
  • Patients who received upper abdominal surgery previously.
  • Pregnant or breast-feeding women.

研究组 & 干预措施

NAC group

Experimental

Patients will receive neoadjuvant chemotherapy (NAC) before the gastrectomy and ERAS.

干预措施: NAC group (Procedure)

Surgery alone group

Active Comparator

Patients will not receive NAC before the gastrectomy and ERAS.

干预措施: Surgery alone group (Procedure)

结局指标

主要结局

Postoperative length of stay

时间窗: 1 month

Postoperative length of stay

次要结局

  • Total protein(1 week)
  • Albumin(1 week)
  • Time to semi-liquid diet(2 weeks)
  • Postoperative complications(2 months)
  • The time to first flatus(1 week)
  • Prealbumin(1 week)

研究者

发起方
JIANG Zhi-Wei
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

JIANG Zhi-Wei

Vice director of Research Institute of General Surgery

Jinling Hospital, China

研究点 (1)

Loading locations...

相似试验